Biogen is betting $5.6 billion that a market barely exists yet can grow into something enormous. The deal, announced this week, to acquire Apellis Pharmaceuticals comes with a twist that reveals more than the headline price: Biogen agreed to pay up to an additional $4 per share in contingent value rights, contingent on SYFOVRE hitting $1.5 billion in annual sales, then $2 billion. To get there from the current combined Apellis revenue of $689 million in 2025, SYFOVRE needs to roughly triple in two years. That math only works if Biogen is right that the real story is the market, not the molecule.
The person who built that molecule spent the early part of his career doing something unusual even by transplant surgery standards. Cedric Francois, Apellis's co-founder and CEO, was part of the team that performed the first successful hand transplantation and later the Louisville Face Transplant program. His move from vascularized composite allotransplantation to complement biology is not the obvious career arc, but it tracks: both fields grapple with the immune system's response to foreign tissue. At Apellis, that meant developing drugs targeting C3, a central protein in the complement cascade — one of the body's first-line inflammatory defense systems that, when dysregulated, drives a range of diseases from rare kidney disorders to retinal degeneration.
The deal structure is the most honest thing in the announcement. Biogen is paying $41 per share in cash, representing an 86 percent premium to Apellis's recent trading price. But the CVR payments are the tell — two $2 tranches tied to SYFOVRE sales milestones, with a third $4 tranche available only in 2031 if prior payments haven't been triggered. That kind of back-loaded contingency says Biogen wants the asset but isn't confident enough to price it fully into the upfront. The eye drug is the uncertainty. EMPAVELI, Apellis's other marketed drug, is the more straightforward bet.
SYFOVRE is the first FDA-approved treatment for geographic atrophy, a leading cause of blindness in which light-sensitive retinal cells die off gradually, creating blind spots that expand over time. The drug won approval in July 2023 based on the Phase 3 OAKS and DERBY studies, which showed it could slow lesion progression by up to 36 percent with monthly injections in the DERBY study — the greatest benefit emerging between months 18 and 24 of treatment. A five-year extension study called GALE found it delayed lesion progression by approximately 1.5 years compared to a sham treatment. That is meaningful clinical benefit in a disease with no prior options.
It also had a rough launch. Within five months of approval, cases of retinal vasculitis — inflammation in retinal blood vessels — were reported in patients receiving SYFOVRE injections, according to The Ophthalmologist. Thirteen cases were documented, including instances of wet AMD development, blurred vision, inflammation, and bleeding beneath the eye's clear lining. Apellis has said the events may stem from a pre-existing polyethylene glycol allergy — a hypothesis that emerged in the months following the reports — and updated the drug's label accordingly. The stock lost roughly half its value in days. The safety issue didn't end SYFOVRE, but it established a ceiling on how enthusiastically eyecare specialists would embrace it.
Mizuho now projects SYFOVRE will peak at $1.08 billion in annual sales in 2033, down from a consensus estimate of $1.29 billion before the downgrade — a 16 percent haircut that reflects persistent challenges with uptake. The competitive picture adds another complication. Astellas's Izervay, which targets the same complement pathway (C5 rather than C3), has been chipping away at SYFOVRE's early-mover advantage and recently posted long-term data positioning itself as a durable option. Geographic atrophy is not yet a winner-take-all market. The question is whether the class expands the overall treated population or primarily redistributes share.
That is where EMPAVELI comes in. The drug generated $689 million in combined 2025 net revenue with SYFOVRE, but its real story is the VALIANT Phase 3 trial, which showed a 68 percent reduction in proteinuria compared to placebo in patients with C3 glomerulopathy, along with stabilization of kidney function and substantial clearance of C3 deposits. C3 glomerulopathy is a rare disease — the kind Apellis originally built for — but the underlying complement biology has applications across a wider range of kidney diseases. Biogen's press release flags felzartamab, acquired as part of the deal, as being in Phase 3 studies for three kidney diseases with the first trial readout expected in the first half of 2027. The combined pipeline suggests Biogen is buying a complement franchise, not just two drugs.
The acquisition price represents roughly 8x the combined 2025 revenue — a premium in line with other immunology acquisitions, but one that also reflects Biogen's need for growth. The company's multiple sclerosis franchise, anchored by Tecfidera and Avonex, has been under sustained pressure from generics and biosimilars. Shopping for late-stage assets in immunology and nephrology is a coherent response. Whether $5.6 billion buys genuine growth or a expensive hedge against franchise erosion is what the CVR structure is designed to answer — and what only time and the GA market can resolve.
The market needs to be built. Less than 10 percent of diagnosed geographic atrophy patients currently receive treatment, according to analyst coverage of Apellis. Half of diagnosed patients never even see an eyecare specialist. That penetration gap is either the investment thesis or the fantasy, depending on how aggressively Biogen can execute on physician education, safety management, and market expansion — and on whether SYFOVRE's first-mover advantage survives what is shaping up to be a more crowded, more competitive complement ophthalmology market than anyone projected two years ago.
